Pluri (PLUR) to Release Earnings on Wednesday

Pluri (NASDAQ:PLUR) will likely be posting its results before the market opens on Wednesday, September 17th. Analysts expect Pluri to post earnings of ($0.73) per share and revenue of $0.40 million for the quarter.

Pluri Price Performance

Shares of PLUR stock opened at $4.72 on Wednesday. The firm has a market cap of $37.15 million, a P/E ratio of -0.85 and a beta of 0.69. Pluri has a fifty-two week low of $3.33 and a fifty-two week high of $7.13. The business’s 50 day moving average price is $5.13 and its 200-day moving average price is $4.77. The company has a debt-to-equity ratio of 51.65, a quick ratio of 4.81 and a current ratio of 4.81.

Institutional Investors Weigh In On Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC bought a new position in Pluri Inc. (NASDAQ:PLUR) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri at the end of the most recent quarter. Institutional investors and hedge funds own 16.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Industrial Alliance Securities set a $12.00 price objective on Pluri in a research report on Monday, June 2nd. Alliance Global Partners assumed coverage on Pluri in a research report on Monday, June 2nd. They issued a “buy” rating and a $12.00 price objective on the stock. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Pluri has an average rating of “Buy” and an average price target of $12.00.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.